# Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

> **NCT05918055** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** KPT-8602
- **DRUG:** Inqovi
- **PROCEDURE:** Bone marrow aspirate
- **PROCEDURE:** Bone marrow biopsy
- **DIAGNOSTIC_TEST:** ECG

## Key facts

- **NCT ID:** NCT05918055
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-14
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Drug company withdrew support.
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918055, "Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes". Retrieved via MORVS 2026-10-28 from https://api.morvs.ai/clinical/NCT05918055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*